Olabir - Olaparib 150mg 30 Tablets (Lynparza) Anticancer Medication

Olabir (OLAPARIB 150 mg) x 30 Tablets

~~$900.00~~ $425.00

Prescription Required

Olabir is an oral anticancer medication containing Olaparib 150 mg, a PARP inhibitor used to treat cancers associated with BRCA gene mutations. It is commonly prescribed for ovarian, breast, pancreatic, and prostate cancers, helping to slow cancer progression and improve survival in advanced stages.

Generic Name	Olaparib
Manufacturer	Aprazer Healthcare Pvt Ltd
Packing	30 Tablets in 1 bottle
Prescribed For	Ovarian and Breast Cancer
Availability	In Stock
Shipping to	USA, UK, Australia, Canada, New Zealand, Philippines, Tunisia, France, Italy, South Korea, Albania, Romania, Hong Kong, Malaysia, Thailand, Singapore, Japan, UAE, Saudi Arabia, Qatar, Kuwait, Georgia, Mexico, and many other countries.

Genuine Medicines

Quick Air Delivery

Secure Payment

24/7 Support

Benefits of OLAPARIB 150 mg

Helps control cancer cell development
Supports treatment for BRCA-mutated cancers
Used in targeted cancer therapy
Helps reduce spread of cancer cells
May improve patient treatment outcomes
Supports comprehensive cancer management

Side Effects

Nausea
Fatigue or tiredness
Vomiting
Shortness of breath (due to anemia)
Low red blood cell count (anemia)
Low white blood cell count (risk of infection)
Low platelet count (risk of bleeding or bruising)
Diarrhea or constipation
Headache
Dizziness
Loss of appetite
Altered taste sensation
Abdominal pain or discomfort

Caution:

Take exactly as prescribed.
Do not skip or stop doses.
Inform your doctor of lung, liver, or kidney problems.
Monitor blood counts regularly.
Avoid use during pregnancy and breastfeeding.
Do not share medication.

Disclaimer

This website operates in compliance with applicable pharmaceutical laws. All content and data available on this website are intended solely for informational purposes. The information provided is not a substitute for professional medical advice, diagnosis, or treatment. Information provided here is for general awareness and does not replace medical advice. We strongly encourage you to consult a qualified healthcare professional for guidance.

Author

Reviewed By

Dr. Abhinav Narang

Doctor of Medicine (MD) | Professional Interest in Oncology

Dr. Abhinav Narang holds a Doctor of Medicine (MD) degree and has a professional interest in oncology and cancer care. His interests include anticancer therapies, monitoring treatment response, managing treatment-related side effects and providing supportive care throughout the patient’s treatment journey.